A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma - Trial NCT06102525
Access comprehensive clinical trial information for NCT06102525 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Rznomics, Inc. and is currently Not yet recruiting. The study focuses on Glioblastoma. Target enrollment is 43 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Rznomics, Inc.
Timeline & Enrollment
Phase 1/2
Oct 01, 2023
May 01, 2029
Primary Outcome
Number of dose limiting toxicities (DLTs),Maximum tolerated dose (MTD) or maximum administered dose (MAD) dose(MAD) and select the recommended Phase 2 dose (RP2D) of RZ-001 in combination with VGCV,Number of participants with treatment-related adverse events as assessed by NCI-CTCAE,Number of participants with significant laboratory abnormalities as assessed by NCI-CTCAE,Overall survival (OS)
Summary
This is a Phase 1/2a, open-label study to evaluate the safety, tolerability, immunogenicity,
 and preliminary clinical activity of RZ-001 administered in combination with VGCV in subjects
 with hTERT-positive GBM.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06102525
Non-Device Trial